James L. Murray

8.0k citations

176 papers · 5.8k indexed · h-index 41

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 1%
- Immunotherapy and Immune Responses

Papers in

Immunology 75
- Immunotherapy and Immune Responses 59
- T-cell and B-cell Immunology 20
Oncology 85
- HER2/EGFR in Cancer Research 25
- Cancer Immunotherapy and Biomarkers 24
- Cancer Treatment and Pharmacology 14

Co-authors: Nuhad K. Ibrahim Gabriel N. Hortobágyi Vicente Valero Michael G. Rosenblum Daniel J. Booser Constantin G. Ioannides Thomas Hodge George E. Peoples
Journals: Journal of Clinical Oncology (27 papers)Journal of Immunotherapy (9 papers)Cancer Immunology Immunotherapy (9 papers)Cancer (5 papers)JNCI Journal of the National Cancer Institute (4 papers)
Partner nations: United States United Kingdom Greece

In The Last Decade

James L. Murray

174 papers receiving 5.6k citations

Peers

Countries citing papers authored by James L. Murray

Since Specialization

Citations

This map shows the geographic impact of James L. Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Murray more than expected).

Fields of papers citing papers by James L. Murray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Murray. The network helps show where James L. Murray may publish in the future.

Co-authors

The 25 scholars most cited alongside James L. Murray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James L. Murray Line = papers co-authored together James L. Murray links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The National Joint Registry 22 years on: what have we learned about knee replacements? Orthopaedics and Trauma ·Paul M. Sutton, James L. Murray	2025	4
2	Comparison of Internet and Telephone Interventions for Weight Loss Among Cancer Survivors: Randomized Controlled Trial and Feasibility Study JMIR Cancer ·Matthew G. Cox, Karen Basen‐Engquist, Cindy L. Carmack, Janice A. Blalock, Yisheng Li, James L. Murray, Louis L. Pisters, Miguel A. Rodrı́guez-Bigas, Jaejoon Song, Emily C. Martin, Wendy Demark‐Wahnefried	2017	15
3	Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence Annals of Oncology ·Elizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski, James L. Murray, Nathan M. Shumway, Jennifer K. Litton, Diane F. Hale, Sonia A. Perez, Eleftheria A. Anastasopoulou, R Loire, Sathibalan Ponniah, Constantin N. Baxevanis, Eric von Hofe, Michael Papamichail, Герцен Оксана Павловна	2016	80
4	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer Cancer ·Rashmi K. Murthy, Ankur Varma, Cernat Laura, Kenneth R. Hess, Elliana Young, James L. Murray, Bui Dai, Stacy L. Moulder, Amal Melhem‐Bertrandt, Sharon H. Giordano, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobágyi, Francisco J. Esteva	2014	33
5	Identification of Cellular Proteins Required for Replication of Human Immunodeficiency Virus Type 1 AIDS Research and Human Retroviruses ·Natallia Dziuba, Monique R. Ferguson, William A. O’Brien, Anthony Sanchez, Andrew Prussia, Gerlin Eduardo Hernández-Angulo, Brian Friedrich, Guangyu Li, Michael W. Shaw, Jinsong Sheng, Thomas Hodge, Donald H. Rubin, James L. Murray	2012	28
6	Therapeutic Breast Cancer Vaccines BioDrugs ·Nathan M. Shumway, Nuhad K. Ibrahim, Sathibalan Ponniah, George E. Peoples, James L. Murray	2009	24
7	Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma Cancer Research ·James L. Murray, S Ortega Guzman, Kouichiro Kawano, Clay L. Efferson, Jeffrey E. Lee, Merrick I. Ross, Xinhui Wang, Soldano Ferrone, Constantin G. Ioannides	2004	25
8	Ii-Key/HER-2/ neu MHC class-II antigenic epitope vaccine peptide for breast cancer Cancer Immunology Immunotherapy ·Л.А Черная, Nikoletta L. Kallinteris, Minzhen Xu, Joseph V. Gulfo, Robert E. Humphreys, James L. Murray	2004	40
9	Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. PubMed ·Byung Kyun Ko, Clay L. Efferson, Kouichiro Kawano, Henry M. Kuerer, 隆太川端, James L. Murray, Constantin G. Ioannides	2004	3
10	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia Cancer Biotherapy and Radiopharmaceuticals ·Russell J. Schilder, Arturo Molina, Nancy L. Bartlett, Thomas E. Witzig, Leo I. Gordon, James L. Murray, Kathleen Keller, Hua Wang, Gregory A. Wiseman, Christine A. White	2004	29
11	Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. PubMed ·James L. Murray, Л.А Черная, Donna Przepiorka, Richard W. Mainzer, Nuhad K. Ibrahim, Daniel J. Booser, Gabriel N. Hortobágyi, Andrzej P. Kudelka, Kenneth H. Grabstein, Martin A. Cheever, Constantin G. Ioannides	2002	119
12	Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex The Journal of Immunology ·Oscar Mauricio Rios Malavera, Darrick Carter, Clay L. Efferson, Nancy E. Ward, Kouichiro Kawano, Bryan Fisk, Andrzej P. Kudelka, David M. Gershenson, James L. Murray, Catherine A. O’Brian, Constantin G. Ioannides	2002	23
13	Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity Molecular and Cellular Biochemistry ·Oscar Mauricio Rios Malavera, Nancy E. Ward, Catherine A. O’Brian, Wang Yi-Ting Laureen, Helle Kjær, Kriss Wegemer, James L. Murray, Andrzej P. Kudelka, David M. Gershenson, Constantin G. Ioannides	2001	27
14	Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. PubMed ·G. Yoo, Mien‐Chie Hung, Gabriel Lopez‐Berestein, Klaus Zierer, John F. Ensley, Masaru Harada, FATMA ODABAŞI, Thomas C. Reynolds, James L. Murray	2001	87
15	Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. PubMed ·Michel Cointat, George E. Peoples, James L. Murray, S Ortega Guzman, David M. Gershenson, Constantin G. Ioannides	2000	40
16	Clinical trials of HER-2/neu-specific vaccines. PubMed ·James L. Murray, Donna Przepiorka, Constatin G. Ioannides	2000	28
17	Secretion of CXC Chemokine IP-10 by Peripheral Blood Mononuclear Cells from Healthy Donors and Breast Cancer Patients Stimulated with HER-2 Peptides Journal of Interferon & Cytokine Research ·Tom V. Lee, Dong‐Kyu Kim, George E. Peoples, Oscar Mauricio Rios Malavera, James L. Murray, David M. Gershenson, Constantin G. Ioannides	2000	10
18	Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. PubMed ·Todd M. Tuttle, Michel Cointat, 李清萍, Jeffrey E. Lee, Ayşegül A. Şahin, Terry L. Smith, Kenneth H. Grabstein, J.Taylor Wharton, Constantin G. Ioannides, James L. Murray	1998	44
19	Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes. PubMed ·Bryan Fisk, Michel Cointat, Mohammad Ehsan Akhtar, C A O'Brian, A P Kudelka, James L. Murray, J. Taylor Wharton, Constantin G. Ioannides	1997	28
20	Changes in an HER-2 Peptide Upregulating HLA-A2 Expression Affect Both Conformational Epitopes and CTL Recognition Journal of Immunotherapy ·Bryan Fisk, Cherylyn A. Savary, Luo Qu, Catherine A. O’Brian, James L. Murray, J. Taylor Wharton, Constantin G. Ioannides	1995	25

About James L. Murray

James L. Murray is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Virology and Cancer Research, having authored 176 papers that have together received 5.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (66 papers), Immunotherapy and Immune Responses (59 papers), HER2/EGFR in Cancer Research (25 papers), Cancer Immunotherapy and Biomarkers (24 papers), Radiopharmaceutical Chemistry and Applications (22 papers), T-cell and B-cell Immunology (20 papers), Glycosylation and Glycoproteins Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). The work is most often cited by research in Oncology (2.6k citations), Immunology (1.9k citations), Radiology, Nuclear Medicine and Imaging (1.8k citations), Virology (285 citations) and Cancer Research (657 citations). James L. Murray has collaborated with scholars based in United States, United Kingdom and Greece. Frequent co-authors include Nuhad K. Ibrahim, Gabriel N. Hortobágyi, Vicente Valero, Michael G. Rosenblum, Daniel J. Booser, Constantin G. Ioannides, Thomas Hodge, George E. Peoples, Francisco J. Esteva and L. Lamki. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Cancer Immunology Immunotherapy, Cancer and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact